Home Cart Sign in  
Chemical Structure| 2092925-89-6 Chemical Structure| 2092925-89-6

Structure of Palazestrant
CAS No.: 2092925-89-6

Chemical Structure| 2092925-89-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Palazestrant is an anti-estrogen medication with anti-tumor properties, often used in combination with HER2 inhibitors to suppress ER+/HER2+ cancer types.

Synonyms: OP-1250

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Palazestrant

CAS No. :2092925-89-6
Formula : C28H36FN3O
M.W : 449.60
SMILES Code : CCCN1CC(OC2=CC=C([C@H]3N(CC(C)(F)C)[C@H](C)CC4=C3NC5=C4C=CC=C5)C=C2)C1
Synonyms :
OP-1250
MDL No. :N/A

Safety of Palazestrant

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04505826 Hormone Receptor Positive Brea... More >>st Carcinoma|HER2-negative Breast Cancer Less << PHASE1|PHASE2 ACTIVE_NOT_RECRUITING 2025-07-24 UCLA Hematology/Oncology, Los ... More >>Angeles, California, 90404, United States|University of Colorado, Aurora, Colorado, 80045, United States|University of Miami, Sylvester Comprehensive Cancer Center, Deerfield Beach, Florida, 33442, United States|Advent Health, Orlando, Florida, 32804, United States|Florida Cancer Center, Sarasota, Florida, 34232, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, 30322, United States|Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, 46202, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, 64111, United States|Montefiore Medical Center, Bronx, New York, 10461, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, 44195, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States|OHSU Knight Cancer Institute, Portland, Oregon, 97239, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|Macquarie University, Sydney, New South Wales, 2109, Australia|Westmead, Westmead, New South Wales, 2145, Australia|ICON Cancer Centre, Auchenflower, Queensland, 4066, Australia|Cancer Research South Australia, Adelaide, South Australia, 5000, Australia Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.22mL

0.44mL

0.22mL

11.12mL

2.22mL

1.11mL

22.24mL

4.45mL

2.22mL

 

Historical Records

Categories